The content on this site is intended for healthcare professionals only
Dr Chris Gallagher talks to ecancer at the 2013 NCRI Cancer Conference in Liverpool about the PETROC study.
The trial is a meta analysis of phase III trials of post operative intraperitoneal chemotherapy in epithelial ovarian cancer, fallopian tube and primary peritoneal cancer.
In the 853 patients that participated, with 6 years follow-up, there was a reduction of 16% in risk of progression, 17% in risk of death, and increased median progression free (20 to 25 months),and overall (51 to 62 months )survival.
PETROC/OV21 is designed to investigate women not able to be optimally debulked at primary surgery who have had primary IV chemotherapy and optimal interval debulking followed by IVor IP treatment, with dose paclitaxel plus carboplatinor cisplatin.
The study reached the conclusion that intraperitoneal chemotherapy after interval debulking surgery is feasible and safe.
ESMO 2025: Latest developments in endometrial cancer
ESMO and WCLC: Latest developments in EGFR mutated NSCLC
Choosing the right Tyrosine Kinase Inhibitors (TKI) for CML Patients
Advancements in head and neck cancer treatment in India
New NK-1 inhibitor HR20013 shows promising results in preventing chemotherapy-induced nausea and vomiting in NSCLC patients
Advancements in paediatric Acute lymphoblastic leukemia management
Choosing Wisely in endometrial & cervix cancers: Medical therapy
Low-dose olanzapine after highly emetogenic chemotherapy can be the new standard of care for solid tumours
Induction chemotherapy added to chemoradiation improves PFS and OS in advanced cervical cancer
